N/A N=38 Treatment

Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors

Lung Cancer

Bottom Line

View on ClinicalTrials.gov: NCT00632281 ↗

Enrolled (actual)

Serious AEs

52.6%

Results posted

Feb 2012

Primary outcome: Primary: Disease Status — 84; 78; 55; 54 percentage of participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Stereotactic Body Radiation Therapy (Radiation)
Age: Pediatric, Adult, Older Adult
Sex: All
Sponsor: University of Florida
Primary completion: Oct 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Disease Status	84; 78; 55; 54	—
SECONDARY Toxicity ot the Thorax	30; 2; 32; 8	—

Summary

The purpose of this research study is to determine if Stereotactic Body Radiation Therapy(SBRT) is a good way to treat tumors near the thorax. Stereotactic Body Radiation Therapy (SBRT) is a general term for a group of techniques that are designed to deliver radiation therapy in a way that damages normal tissues less than conventional radiotherapy. The two features that distinguish SBRT from conventional therapy are procedures that decrease errors in patient positioning and technology that results in a radiation dose distribution that conforms more tightly to the tumor target. Patients will receive either 48 Gy or 60 Gy fractions depending on the type of tumor. The majority of patients will be treated in 1 week, Monday through Friday, with Wednesday off.

Eligibility Criteria

Inclusion Criteria

Informed consent to participate in this protocol
Patients of all ages are eligible
All tumor types are eligible
Patients with prior thoracic radiotherapy and/or surgery are eligible
Tumor size ≤ 5 cm

Exclusion Criteria

The subject is eligible for surgical resection or prefers treatment on this protocol to surgical resection.
Less than 1 year since original radiation to thorax for retreatment patients.
More than 2 tumors requiring SBRT
The patient cannot be positioned reproducibly due to pain or other factors

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00632281). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.